JHVEPhoto/iStock Editorial via Getty Images
Amgen (AMGN) is facing a possible EU withdrawal of its rare-disorder therapy, Tavneos, after an expert panel of the European Medicines Agency recommended its marketing authorization be revoked due to data integrity issues.
Also Read
The decision came after the EMA’s human
Source link
#Amgen #faces #withdrawal #Tavneos #AMGNNASDAQ
